

Antimalarial Efficacy of Aqueous Extract of *Strychnos ligustrina* and Its Combination with Dihydroartemisinin and Piperaquine Phosphate (DHP) against *Plasmodium berghei* Infection

Umi Cahyaningsih^{1,*} , Siti Sa'diah^{2,5}, Wasrin Syafii³, Rita Kartika Sari^{3,5} , Abdul Jafar Maring⁴,
Arifin Budiman Nugraha¹

¹Department of Animal Diseases and Veterinary Public Health, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, Indonesia; ²Department of Anatomy, Physiology, and Pharmacology, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, Indonesia; ³Department of Forest Products, Faculty of Forestry and Environment, IPB University, Bogor, Indonesia; ⁴Research and Development Institute of Non-Timber Forest Product Technology, Mataram, Indonesia; ⁵Tropical Biopharmaca Research Center, IPB University, Bogor, Indonesia

Abstract: The development of drug resistance is one of the most severe concerns of malaria control because it increases the risk of malaria morbidity and death. A new candidate drug with antiplasmodial activity is urgently needed. This study evaluated the efficacy of different dosages of aqueous extract of *Strychnos ligustrina* combined with dihydroartemisinin and piperaquine phosphate (DHP) against murine *Plasmodium berghei* infection. The BALB/c mice aged 6-8 weeks were divided into 6 groups, each consisting of 10 mice. The growth inhibition of compounds against *P. berghei* was monitored by calculating the percentage of parasitemia. The results showed that the mice receiving aqueous extract and combination treatment showed growth inhibition of *P. berghei* in 74% and 94%, respectively. *S. ligustrina* extract, which consisted of brucine and strychnine, effectively inhibited the multiplication of *P. berghei*. The treated mice showed improved hematology profiles, body weight, and temperature, as compared to control mice. Co-treatment with *S. ligustrina* extract and DHP revealed significant antimalarial and antipyretic effects. Our results provide prospects for further discovery of antimalarial drugs that may show more successful chemotherapeutic treatment.

Key words: *Strychnos ligustrina*, antiplasmodial activity, dihydroartemisinin piperaquine phosphate, *Plasmodium berghei*

INTRODUCTION

Malaria is a disease caused by *Plasmodium*, which belongs to apicomplexan parasites. The disease is transmitted by mosquito vectors. Several *Plasmodium* species, such as *P. vivax*, *P. falciparum*, *P. malariae*, *P. ovale*, and *P. knowlesi* cause human infections. Those parasites are widely distributed worldwide. Malaria is still one of the most highly pathogenic diseases and remains a significant public health problem. Malaria mortality was reported in more than 60% of infected children worldwide [1].

Malaria situation has worsened due to the emergence of *Plasmodium* species that are resistant to antimalarial drugs. This could lead to more obstacles that hinder disease control [2].

The World Health Organization recommends the artemisinin-based combination therapy for treating malaria [1]. Natural compounds can be used as alternative antimalarial drugs that can be utilized in artemisinin-based combination therapies [3]. The combination could enhance the potency of natural extracts and minimize parasite resistance.

In Indonesia, many natural compounds are used as alternative medicines. One of these natural compounds is *Strychnos ligustrina*. The aqueous extract of *S. ligustrina* demonstrated an antimalarial activity in mice. Two compounds, including flavonoids and alkaloids, play important roles in antimalarial activity. Previous studies have shown that ethanol extract of *S. ligustrina* wood was successively exhibiting potent antimalarial activity against *P. falciparum* multiplication. Further studies have shown that the antimalarial activity of aqueous extract of *S. ligustrina* extracted from maceration with water was higher than that of ethanol extract. Brucine (indole alkaloid) was the dominant compound in both the aqueous and ethanol extracts. The aqueous extract contains a higher level of brucine

•Received 28 April 2022, revised 24 July 2022, accepted 1 August 2022.

*Corresponding author (umi-ch@apps.ipb.ac.id)

© 2022, Korean Society for Parasitology and Tropical Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

(24.9%) than the ethanol extract (11.6%) [4,5].

Therefore, this study aimed to evaluate the efficacy of aqueous extract of *S. ligustrina* and combination treatment of dihydroartemisinin and piperazine phosphate (DHP) and aqueous extract of *S. ligustrina* against *Plasmodium berghei* in an infected mice model. Our findings demonstrated that antimalarial compounds of *S. ligustrina* may improve antimalarial efficacy when combined with DHP.

MATERIALS AND METHODS

Ethical consideration

The Animal Ethics Commission of Bogor Agricultural University has approved the in vivo experiments on mice (accession number: 154-2019 IPB).

Plant sample

Strychnos ligustrina wood samples were obtained from Dompu West Nusa Tenggara, Indonesia. The collected plant sample was identified by the Laboratory of Silviculture, Faculty of Agriculture, University of Mataram.

Preparation of crude extract

The extraction was carried out on a pilot project scale at Fits Mandiri Company, Bogor, Indonesia. A total of 31 kg of *S. ligustrina* wood shavings (moisture content of 11.8%) was macerated with distilled water (5% Brix: 5 g of solid in 100 g of solution). Extraction was carried out twice. The extracted filtrate was then dried using a spray dryer to produce an extract powder. The standard compounds used for the high-performance liquid chromatography (HPLC) analysis were strychnine and brucine (Sigma, Darmstadt, Germany).

High-performance liquid chromatography (HPLC) analysis

Brucine and strychnine components in *S. ligustrina* extract were quantified using reverse-phase HPLC with a C18 column. Acetonitrile and water were employed as the mobile phase, using a 5-95% acetonitrile gradient elution method for 30 min. The intensity of the chemical at the concentration used was measured at wavelength 254 nm.

Parasite

The *P. berghei* Antwerpen-Kasapa (ANKA) strain was obtained from the National Institute of Health Research and De-

velopment, Indonesian Ministry of Health. The parasites were passed by inoculating intraperitoneally from the infected mice to the healthy mice every week.

In vivo antimalarial inhibition test

The growth inhibitory effect of antimalarial drugs was determined using mice infected with *P. berghei*. The BALB/c mice aged 6-8 weeks were divided into 6 groups, consisting of 10 mice each. Groups A and B comprised healthy and infected-untreated mice, respectively. Group C, used as the control group, received 222 mg/kg body weight (BW) of DHP. Group D received 300 mg/kg BW of aqueous extract of *S. ligustrina*. Group E received a combination of 111 mg/kg BW of DHP and 200 mg/kg BW of aqueous extract of *S. ligustrina*, and Group F received 111 mg/kg BW of the control drug (DHP). The drugs were administered orally. The treatment was started when the average parasitemia reached 10% on day 6 post-infection (p.i.). The treatment was started and continued for 4 consecutive days (days 6 to 10 p.i.).

Inoculation of *P. berghei*

Before starting the experiment, the parasites were obtained from the frozen stock at -80°C and injected intraperitoneally to the mice. At least 3 times of passage of the parasites from the infected mouse to the healthy mouse were maintained. Subsequently, after the passages, the donor mouse was prepared by injecting parasites intraperitoneally. Parasitemia was monitored by using Giemsa-stained blood smears every 2 days. When the parasitemia reached approximately 20%, the mice were euthanized, and blood was collected via cardiac puncture. Blood was diluted with phosphate buffered saline (PBS); 0.5 ml of blood contained 2×10^6 *P. berghei* infected red blood cells (RBCs). Each group, except for group A, received 0.5 ml of infected RBCs intraperitoneally [6].

Monitoring of parasitemia

Parasitemia was monitored every 2 days by preparing blood smears on a microscope slide. The slides were dried, fixed, and stained with 10% Giemsa [7]. The thin blood smears were examined using a microscope under $1,000\times$ magnification. The parasites were counted for every 1,000 RBCs.

Monitoring of hematological profiles, body weight, and temperature

The body weight and temperature were measured every 2

Table 1. Brucine and strychnine levels in *Strychnos ligustrina* extract samples

Compound	Conc. standard (ppm)	t _r (min)	Peak		Conc. equivalent (ppm)	Extract conc. (mg/g extract)
			Standard	Extract		
Brucine	100.6	10.6	3,013,366	2,055,290	68.6	13.5
Strychnine	99.9	11.7	4,333,517	2,163,051	49.9	9.8




Fig. 1. Effect of drug treatment on the growth of *Plasmodium berghei* in mice. The parasitemia rate after treatment with 300 mg/kg body weight (BW) of mono-extract of *Strychnos ligustrina*, 111 mg/kg BW of dihydroartemisinin and piperazine phosphate (DHP), and their combination therapy. The treatment regime was started from day 6 to 10 post-infection. The data are shown as a mean from 2 experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, compared to the group B by student *t*-test.

days during the experimental period. The hematological profiles were evaluated every 4 days using a hematological analyzer (Medically Automatic Hematology Analyzer Mindray BC-2800 Vet, Shenzhen, China). All parameters were assessed for 20 days post-infection.

Data analysis

All variables were analyzed using the Student's *t*-test. The difference in each variable between the untreated and treated groups was considered statistically significant when $P < 0.05$.

RESULTS

The chromatograms of brucine and strychnine standard compounds were found with retention times of 10.6 and 11.7 min, respectively (Supplementary Fig. S1). Using the same separation process, extract analysis was done on a sample concentration of 5,080 ppm. Since identical retention times were found in the standard chromatograms for brucine and strychnine, retention time similarity analysis revealed that the extract samples contained brucine and strychnine (Supplementary

Fig. S2). By comparing the peak area of brucine and strychnine retention times on the standard chromatograms and extract samples, the quantitative results demonstrated that amount of brucine was higher than that of strychnine. The concentrations of brucine and strychnine were 13.5 and 9.8 mg/g extract, respectively (Table 1).

In vivo antimalarial inhibition test

The aqueous extract of *S. ligustrina* had an antiplasmodial activity. This was observed from the parasitemia and inhibition activity, which are comparable to other groups. Overall, the peak of parasitemia was observed on day 7 p.i. for groups B (infected-untreated), C (222 mg/kg BW of DHP), and E (combination treatment of 200 mg/kg BW of aqueous extract of *S. ligustrina* and 111 mg/kg BW of DHP), while group D (300 mg/kg BW of aqueous extract of *S. ligustrina* parasitemia) peaked on day 6 p.i. The highest percentages of parasitemia for groups B, C, D, E, and F were 21.5%, 19.5%, 22.1%, 11.5%, and 12.5%, respectively (Fig. 1).

Hematology profiles

Group D, which received 300 mg/kg BW of aqueous extract of *S. ligustrina*, showed a decrease in RBC count and hemoglobin and hematocrit levels, as compared to group B (untreated-uninfected). Moreover, no statistically significant difference ($P > 0.05$) was found between groups D and A (negative control) (Fig. 2).

Survival rate

The treated groups (C, D, E, and F) were survived until 20 days p.i. The 20-day survival rates after infection were found to be 34%, 42%, 38%, and 40%, respectively, in animals treated with the extract alone, control drug, combination treatment, and half dose of the control drug (Fig. 3).

Body weight and temperature

The treated group did not show parasite-induced weight reduction, as compared to group A (negative control). In contrast, infected-untreated group showed a weight reduction, es-




Fig. 2. Hematology profiles of mice from day 2 to 16 post-infection. Hematology profiles, including hematocrit (A), hemoglobin (B), and red blood cells (C) were monitored every 4 days. All data obtained from the selected mouse are presented as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, compared to the group B by student t -test.




Fig. 3. Survival rate of mice in the 5 different groups infected with *Plasmodium berghei*.




Fig. 4. Body weight and temperature of mice from 2 to 18 days post-infection. Body weight (A) and temperature (B) were monitored every 2 days. All data obtained from 10 mice are expressed as means. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ compared to the group B by t -test.

pecially on days 12 to 16 p.i. The body temperature of the infected-untreated group dramatically decreased from 6 to 18 days p.i. However, the treated-infected group maintained their temperature, as compared to the healthy mice (Fig. 4).

DISCUSSION

The development of drug resistance is one of the most severe concerns to malaria control since it leads to an increase in the rates of malaria morbidity and death. The resistance to the artemisinin and non-artemisinin components has recently arisen in the Southeast Asian regions [1]. A new candidate drug with a reliable antiplasmodial activity, such as an herb extract, is urgently needed [8].

Our findings showed that the single usage of the extract and combination treatment inhibited the growth of *P. berghei* by 74% and 94%, respectively, as compared to the untreated group. The mice treated with the extract alone and combination therapy showed the highest percentage of parasitemia on days 7 and 8, respectively. Even though single usage of the extract and combination treatments were less effective than DHP against murine *P. berghei* infection, they showed better inhibition than the control drug. Interestingly, on day 7 p.i., the group treated with 300 mg/kg BW of aqueous extract of *S. ligustrina* had the highest parasitemia rate (22.1%). The parasitemia rate of the aqueous group was dramatically reduced by

12% on day 8 p.i. (Fig. 1). This finding showed that a single extract of *S. ligustrina* contained a compound that inhibited the multiplication of *P. berghei*. Since a single extract of 300 mg/kg BW was administered, it could be classified as having reliable antiplasmodial efficacy [8]. Previous studies also reported that similar plants belong to *Strychnos* had antimalarial activity [9-12]. In this study, single extract treatment and combination treatment inhibited *P. berghei* proliferation. In addition, the aqueous extract improved hematological profiles, body weight, and temperature. Our study showed that aqueous extract of *S. ligustrina* contained high antiplasmodial active compounds, including brucine and strychnine, which is consistent with the previous studies [4,5,13]. Besides the antiplasmodial activity, brucine also has anti-inflammatory and antipyretic activities [14]. In addition, brucine significantly reduced the reactivity induced by the peripheral nerve heat and mechanical stimulations by directly lowering sodium channel excitability [15]. Brucine may also be beneficial to reduce pain and inflammation, thus improve temperature stability. *S. ligustrina* contains a strychnine, which has a toxic effect; however, the concentration used in this study was below the safety limit (9.8 mg/g or 1.2 mg/kg when converted at a 300 mg/kg body weights for 4 days). *S. ligustrina* extract may be a safe antimalarial compound as the dose is lower than the LD50 of strychnine in mice with 2 mg/kg [16,17].

In conclusion, treatment of a single extract of *S. ligustrina* and combination therapy revealed significant antimalarial and antipyretic effects against murine *P. berghei* infection model. Most notably, combining the aqueous extract with DHP may result in a more successful chemotherapeutic treatment. The mode of action of a *S. ligustrina* extract and the efficacy of these derivatives against *Plasmodium* parasites await further study.

ACKNOWLEDGMENTS

This research was funded by the Directorate of Higher Education of the Ministry of Education, Culture, Research, and Technology of the Republic of Indonesia with the IPB Higher Education Research Grant scheme 2021 (contract No. 1/EI/KP.PT.PTNBH/2021) for funding support for this research.

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this study.

REFERENCES

1. World Health Organization. World Malaria Report 2020. World Health Organization. Geneva, Switzerland. 2020.
2. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, D'Alessandro U. Quinine, an old anti-malarial drug in a modern world: Role in the treatment of malaria. *Malar J* 2011; 10: 114. <https://doi.org/10.1186/1475-2875-10-144>
3. Chizhov AV, Schmidt E, Knöll L, Welsch DG. Two-pulse correlations in noisy quantum channels. *Opt Spectrosc* 2001; 91: 406-410. <https://doi.org/10.1134/1.1405220>
4. Syafii W, Sari R, Cahyaningsih U, Anisah LN. Antimalarial activity of the fractions from ethanol extract of *Strychnos ligustrina* blume. *Wood. Res J Med Plant* 2016; 10: 403-408.
5. Manurung H, Kartika R, Syafii W, Cahyaningsih U. Antimalarial activity and phytochemical profile of ethanolic and aqueous extracts of bidara laut (*Strychnos ligustrina* Blum) Wood. *J Korean Wood Sci Tech* 2019; 47: 587-596.
6. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. *Nat Rev Drug Discov* 2004; 3: 509-520. <https://doi.org/10.1038/nrd1416>
7. Peters W, Robinson BL. The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. *Ann Trop Med Parasitol* 1992; 86: 455-465. <https://doi.org/10.1080/00034983.1992.11812694>
8. Muñoz V, Sauvain M, Bourdy G, Callapa J, Rojas I, Vargas L, Tae A, Deharo E. The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosekene Indians. *J Ethnopharmacol* 2000; 69: 139-155. [https://doi.org/10.1016/s0378-8741\(99\)00096-3](https://doi.org/10.1016/s0378-8741(99)00096-3)
9. Fentahun S, Makonnen E, Awas T, Giday M. In vivo antimalarial activity of crude extracts and solvent fractions of leaves of *Strychnos mitis* in *Plasmodium berghei* infected mice. *BMC Complement Altern Med* 2017; 17: 13. <https://doi.org/10.1186/s12906-016-1529-7>
10. Frederich M, Hayette M, Tits M, De Mol P, Angenot L. In vitro activities of strychnos alkaloids and extracts against *Plasmodium falciparum*. *Antimicrob Agents Chemother* 1999; 43: 2328-2331. <https://doi.org/10.1128/AAC.43.9.2328>
11. Angenot L, Mol P De, Goffin E, Hayette MP, Tits M, Frédéric M. In vitro screening of some *Strychnos* species for antiplasmodial activity. *J Ethnopharmacol* 2005; 97: 535-539. <https://doi.org/10.1016/j.jep.2004.12.011>
12. Tchinda AT, Ngono ARN, Tamze V, Jonville MC, Cao M, Angenot L, Frédéric M. Antiplasmodial alkaloids from the stem bark of *Strychnos malacoclados*. *Planta Med* 2012; 78: 377-382. <https://doi.org/10.1055/s-0031-1280473>
13. Cahyaningsih U, Sa'diah S, Syafii W, Sari RK, Harisyah M, Wahyuningrum M. Effect of after-treatment of *Strychnos ligustrina* extract on the percentage of parasitemia in mice infected with

- Plasmodium berghei*. E3S Web of Conferences 2020; 151: 2019-2021.
14. Lu L, Huang R, Wu Y, Jin JM, Chen HZ, Zhang LJ, Luan X. Brucine: a review of phytochemistry, pharmacology, and toxicology. *Front Pharmacol* 2020; 11: 377. <https://doi.org/10.3389/fphar.2020.00377>
 15. Yu G, Qian L, Yu J, Tang M, Wang C, Zhou Y, Geng X, Zhu C, Yang Y, Pan Y, Shen X, Tang Z. Brucine alleviates neuropathic pain in mice via reducing the current of the sodium channel. *J Ethnopharmacol* 2019; 233: 56-63. <https://doi.org/10.1016/j.jep.2018.12.045>
 16. Guo R, Wang T, Zhou G, Xu M, Yu X, Zhang X, Sui F, Li C, Tang L, Wang Z. Botany, phytochemistry, pharmacology and toxicity of *Strychnos nux-vomica* L.: a review. *Am J Chin Med* 2018; 46: 1-23. <https://doi.org/10.1142/S0192415X18500015>
 17. Maher A, Radwan R, Breitingen HG. In vivo protection against strychnine toxicity in mice by the glycine receptor agonist ivermectin. *Biomed Res Int* 2014; 2014: 640790. <https://doi.org/10.1155/2014/640790>